Annelies Van Eyck1, Ann De Guchtenaere2, Luc Van Gaal3, Wilfried De Backer4, Stijn L Verhulst5, Kim Van Hoorenbeeck5. 1. Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium; Department of Pediatrics, Antwerp University Hospital, Edegem, Belgium. Electronic address: Annelies.vaneyck@uantwerpen.be. 2. Zeepreventorium VZW, De Haan, Belgium. 3. Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium; Department of Endocrinology, Diabetology, and Metabolism, Antwerp University Hospital, Edegem, Belgium. 4. Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium; Department of Pulmonology, Antwerp University Hospital, Edegem, Belgium. 5. Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium; Department of Pediatrics, Antwerp University Hospital, Edegem, Belgium.
Abstract
OBJECTIVE: To investigate clinical factors that could predict residual sleep-disordered breathing (SDB) after weight loss. STUDY DESIGN: Obese subjects between 10 and 19 years of age were recruited while entering an in-patient weight loss treatment program. All subjects underwent anthropometry and sleep screening using a portable device at baseline and after 4-6 months of therapy. Sleep and International Study of Asthma and Allergies in Childhood questionnaires were completed at baseline. RESULTS: A total of 339 patients were included. Median age was 15.4 years (10.1-19.1). Body mass index z score at baseline was 2.75 ± 0.42, and 35% of subjects were boys. SDB was present in 32%. After a mean decrease in body mass index z score of 32%, residual SDB was found in 20% of subjects with SDB at baseline. Subjects with more severe SDB (OR 1.18; CI 1.01-1.34; P = .02) and respiratory allergies (OR 7.85; CI 1.20-51.39; P = .03) were at higher risk of developing residual SDB, unlike age, sex, and anthropometric variables. CONCLUSIONS: Weight loss was successful for treating SDB in 80% of patients. More severe SDB and the presence of respiratory allergies at baseline were associated with a higher risk of residual SDB after weight loss.
OBJECTIVE: To investigate clinical factors that could predict residual sleep-disordered breathing (SDB) after weight loss. STUDY DESIGN: Obese subjects between 10 and 19 years of age were recruited while entering an in-patientweight loss treatment program. All subjects underwent anthropometry and sleep screening using a portable device at baseline and after 4-6 months of therapy. Sleep and International Study of Asthma and Allergies in Childhood questionnaires were completed at baseline. RESULTS: A total of 339 patients were included. Median age was 15.4 years (10.1-19.1). Body mass index z score at baseline was 2.75 ± 0.42, and 35% of subjects were boys. SDB was present in 32%. After a mean decrease in body mass index z score of 32%, residual SDB was found in 20% of subjects with SDB at baseline. Subjects with more severe SDB (OR 1.18; CI 1.01-1.34; P = .02) and respiratory allergies (OR 7.85; CI 1.20-51.39; P = .03) were at higher risk of developing residual SDB, unlike age, sex, and anthropometric variables. CONCLUSIONS:Weight loss was successful for treating SDB in 80% of patients. More severe SDB and the presence of respiratory allergies at baseline were associated with a higher risk of residual SDB after weight loss.
Authors: Eline Vermeiren; Marijke Ysebaert; Kim Van Hoorenbeeck; Luc Bruyndonckx; Kristof Van Dessel; Maria Van Helvoirt; Ann De Guchtenaere; Benedicte De Winter; Stijn Verhulst; Annelies Van Eyck Journal: Eur J Clin Nutr Date: 2020-09-11 Impact factor: 4.016
Authors: Sanae Makhout; Eline Vermeiren; Karolien Van De Maele; Luc Bruyndonckx; Benedicte Y De Winter; Kim Van Hoorenbeeck; Stijn L Verhulst; Annelies Van Eyck Journal: Front Med (Lausanne) Date: 2022-01-20